| scholarly article | Q13442814 |
| P2093 | author name string | B Ullman | |
| T Nyström | |||
| M Frick | |||
| A Sjöholm | |||
| A Hedman | |||
| D Nathanson | |||
| U Löfström | |||
| P2860 | cites work | Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 phosphorylation via ETA and CPI-17 dephosphorylation via ETB. | Q44905666 |
| Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. | Q44924385 | ||
| Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy | Q45020436 | ||
| Cardiac metabolism as a target for the treatment of heart failure | Q45027954 | ||
| Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. | Q45930780 | ||
| Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus | Q46220335 | ||
| Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats | Q46750012 | ||
| Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 | ||
| Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. | Q54588963 | ||
| Diastolic Stiffness of the Failing Diabetic Heart | Q58087772 | ||
| Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction | Q58447894 | ||
| Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats | Q59616303 | ||
| Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators | Q73134596 | ||
| Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure | Q79437872 | ||
| Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting | Q80843544 | ||
| Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart | Q81538720 | ||
| Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor | Q84187312 | ||
| Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons | Q28571689 | ||
| Cardiac function in mice lacking the glucagon-like peptide-1 receptor | Q28586718 | ||
| GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. | Q30497661 | ||
| Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy | Q33832036 | ||
| Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database | Q34422144 | ||
| Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy | Q34786386 | ||
| Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans | Q35858769 | ||
| Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats | Q36735857 | ||
| Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans | Q36877627 | ||
| Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity | Q36906298 | ||
| The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance | Q37269274 | ||
| Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. | Q37322877 | ||
| The adrenergic-fatty acid load in heart failure | Q37619839 | ||
| A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans | Q38490894 | ||
| Mechanical properties of primary cilia regulate the response to fluid flow | Q39749829 | ||
| Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study | Q39905736 | ||
| Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure | Q41267217 | ||
| Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
| Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure | Q43191785 | ||
| Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers | Q43638669 | ||
| Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes | Q43726354 | ||
| Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 | ||
| P433 | issue | 4 | |
| P921 | main subject | heart failure | Q181754 |
| patient | Q181600 | ||
| congestive heart failure | Q19000661 | ||
| P304 | page(s) | 926-935 | |
| P577 | publication date | 2012-01-13 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. | |
| P478 | volume | 55 |
| Q34771795 | Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes |
| Q26992979 | Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making |
| Q38057699 | Cardiac metabolism in hypertrophy and heart failure: implications for therapy |
| Q57801699 | Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, |
| Q48022106 | Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus |
| Q41242150 | Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus |
| Q44579003 | Cardiovascular effects of alpha-linolenic acid--a possible role of glucagon-like peptide-1. |
| Q38857056 | Cardiovascular effects of anti-diabetes drugs |
| Q26823085 | Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists |
| Q26741082 | Cardiovascular safety of anti-diabetic drugs |
| Q36302662 | Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes |
| Q27003819 | Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement |
| Q38132470 | Direct cardiovascular effects of glucagon like peptide-1. |
| Q38066566 | Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. |
| Q33708984 | Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
| Q38184929 | Effects of incretin-based therapy in patients with heart failure and myocardial infarction |
| Q47122085 | Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study |
| Q36694694 | Exenatide Reduces Tumor Necrosis Factor-α-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction |
| Q36454284 | Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure |
| Q38179267 | Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus |
| Q38194069 | Extra-pancreatic effects of incretin-based therapies |
| Q33917887 | GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study |
| Q30407530 | GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans |
| Q53502910 | GLP-1 receptor agonists and heart failure in diabetes. |
| Q38122396 | GLP-1 receptor agonists: effects on cardiovascular risk reduction |
| Q58167256 | Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy |
| Q38542098 | Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance |
| Q52673331 | Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. |
| Q33603384 | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas |
| Q88304602 | Has the Time Come to Be More Aggressive With Bariatric Surgery in Obese Patients With Chronic Systolic Heart Failure? |
| Q61851313 | Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel‐group study |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q42736812 | Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection |
| Q38260853 | Incretin-related drug therapy in heart failure |
| Q38008596 | Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. |
| Q39199887 | Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure |
| Q55090958 | Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance. |
| Q38225739 | Newest additions to heart failure treatment |
| Q38286444 | Potential side effects to GLP-1 agonists: understanding their safety and tolerability |
| Q28081569 | Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials |
| Q38042110 | Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease |
| Q38134902 | The cardiovascular safety of incretin-based therapies: a review of the evidence |
| Q38174279 | The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems |
| Q38836416 | Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit |
| Q89766315 | Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure? |
Search more.